| ［1］ |
de Mattos AA, de Mattos AZ, Sartori GDP. The role of elastography in clinically significant portal hypertension[J]. Arq Gastroenterol, 2023, 60(4): 525–535.
|
| ［2］ |
Albillos A, Bañares R, Hernández-Gea V. Portal hypertension: recommendations for diagnosis and treatment. Consensus document sponsored by the Spanish Association for the Study of the Liver (AEEH) and the Biomedical Research Network Centre for Liver and Digestive Diseases (CIBERehd)[J]. Gastroenterol Hepatol, 2025, 48(1): 502208.
|
| ［3］ |
Mendizabal M, Cançado GGL, Albillos A. Evolving portal hypertension through Baveno Ⅶ recommendations[J]. Ann Hepatol, 2024, 29(1): 101180.
|
| ［4］ |
Bai W, Abraldes JG. Noninvasive assessment oesophageal varices: impact of the Baveno Ⅵ criteria[J]. Curr Opin Gastroenterol, 2022, 38(3): 206–215.
|
| ［5］ |
Wang C, Huang Y, Liu C, et al. Diagnosis of clinically significant portal hypertension using CT- and MRI-based vascular model[J]. Radiology, 2023, 307(2): e221648.
|
| ［6］ |
Pun CK, Chang CC, Chuang CL, et al. Dual angiotensin receptor and neprilysin inhibitor reduced portal pressure through peripheral vasodilatation and decreasing systemic arterial pressure in cirrhotic rats[J]. J Chin Med Assoc, 2023, 86(9): 786–794.
|
| ［7］ |
Yuasa M, Yamamoto H, Kageyama K, et al. Splenomegaly negatively impacts neutrophil engraftment in cord blood transplantation[J]. Biol Blood Marrow Transplant, 2020, 26(9): 1689–1696.
|
| ［8］ |
Gralnek IM, Garcia-Pagan JC, Hernández-Gea V. Challenges in the management of esophagogastric varices and variceal hemorrhage in cirrhosis-a narrative review[J]. Am J Med, 2024, 137(3): 210–217.
|
| ［9］ |
de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno Ⅶ-Renewing consensus in portal hypertension[J]. J Hepatol, 2022, 76(4): 959–974.
|
| ［10］ |
Iwakiri Y, Trebicka J. Portal hypertension in cirrhosis: pathophysiological mechanisms and therapy[J]. JHEP Rep, 2021, 3(4): 100316.
|
| ［11］ |
Chen M, Zhao JB, Wu GB, et al. Platelet activation relieves liver portal hypertension via the lymphatic system though the classical vascular endothelial growth factor receptor 3 signaling pathway[J]. World J Gastroenterol, 2025, 31(10): 100194.
|
| ［12］ |
Yang H, Tan M, Gao Z, et al. Role of hydrogen sulfide and hypoxia in hepatic angiogenesis of portal hypertension[J]. J Clin Transl Hepatol, 2023, 11(3): 675–681.
|
| ［13］ |
Jiang C, Liu J, Li R, et al. Clinicopathologic characteristics of liver inflammation and fibrosis in 310 patients with chronic hepatitis B[J]. Zhong Nan Da Xue Xue Bao Yi Xue Ban, 2023, 48(5): 698–706.
|
| ［14］ |
Ghadimi DJ, Ghorani H, Moradi Z, et al. Management of ectopic variceal bleeding with transjugular intrahepatic portosystemic shunt: A systematic review of case reports[J]. Emerg Radiol, 2024, 31(4): 581–594.
|
| ［15］ |
Tan S. Molecular mechanism of portal hypertensive gastropathy: An update[J]. Clin Res Hepatol Gastroenterol, 2024, 48(8): 102423.
|
| ［16］ |
He R, Liu C, Grgurevic I, et al. Validation of Baveno Ⅶ criteria for clinically significant portal hypertension by two-dimensional shear wave elastography[J]. Hepatol Int, 2024, 18(3): 1020–1028.
|
| ［17］ |
Turco L, Reiberger T, Vitale G, et al. Carvedilol as the new non-selective beta-blocker of choice in patients with cirrhosis and portal hypertension[J]. Liver Int, 2023, 43(6): 1183–1194.
|
| ［18］ |
Jiang JJ, Gao C, Mao JF, et al. Effect of endoscopic therapy and drug therapy on prognosis and rebleeding in patients with esophagogastric variceal bleeding[J]. Sci Rep, 2024, 14(1): 7364.
|
| ［19］ |
Wang AJ, Zheng XL, Hong JB, et al. Cap-assisted endoscopic sclerotherapy vs ligation in the long-term management of medium esophageal varices: A randomized trial[J]. Clin Transl Gastroenterol, 2020, 11(12): e00285.
|
| ［20］ |
Hayashi T, Watanabe T, Shibata M, et al. Endoscopic injection sclerotherapy improves liver function compared with endoscopic variceal ligation[J]. Sci Rep, 2021, 11(1): 20479.
|
| ［21］ |
Singh S, Chandan S, Vinayek R, et al. Comprehensive approach to esophageal variceal bleeding: from prevention to treatment[J]. World J Gastroenterol, 2024, 30(43): 4602–4608.
|
| ［22］ |
Stoleru G, Henry Z. Balloon-occluded retrograde transvenous obliteration for treatment of portal hypertensive related varices[J]. Curr Opin Gastroenterol, 2023, 39(3): 140–145.
|
| ［23］ |
ASGE Standards of Practice Committee, Desai M, Ruan W, et al. American Society for Gastrointestinal Endoscopy guideline on the diagnosis and management of GERD: summary and recommendations[J]. Gastrointest Endosc, 2025, 101(2): 267–284.
|
| ［24］ |
Hu Y, Zhou M, Liu D, et al. Risk factors for rebleeding after endoscopic injection of cyanoacrylate glue for gastric varices: A systematic review and meta-analysis[J]. Dig Dis Sci, 2024, 69(8): 2890–2903.
|
| ［25］ |
Jhajharia A, Yadav S, Singh S, et al. Endoscopic ultrasonography-guided coil embolization and cyanoacrylate injection versus cyanoacrylate injection alone for gastric varices: A randomized comparative study[J]. Endoscopy, 2025, 57(2): 107–115.
|
| ［26］ |
Paleti S, Nutalapati V, Fathallah J, et al. Balloon-occluded retrograde transvenous obliteration (BRTO) versus transjugular intrahepatic portosystemic shunt (TIPS) for treatment of gastric varices because of portal hypertension: A systematic review and meta-analysis[J]. J Clin Gastroenterol, 2020, 54(7): 655–660.
|
| ［27］ |
Qi WL, Wen J, Wen TF, et al. Prognosis after splenectomy plus pericardial devascularization vs transjugular intrahepatic portosystemic shunt for esophagogastric variceal bleeding[J]. World J Gastrointest Surg, 2023, 15(8): 1641–1651.
|
| ［28］ |
Weinzirl J, Garnitschnig L, Scheffers T, et al. Splenic rhythms and postprandial dynamics in physiology, portal hypertension, and functional hyposplenism: A review[J]. Digestion, 2021, 102(3): 326–334.
|
| ［29］ |
Kondo R, Kage M, Iijima H, et al. Pathological findings that contribute to tissue stiffness in the spleen of liver cirrhosis patients[J]. Hepatol Res, 2018, 48(12): 1000–1007.
|
| ［30］ |
Kang SH, Kim MY, Baik SK. Novelties in the pathophysiology and management of portal hypertension: new treatments on the horizon[J]. Hepatol Int, 2018, 12(Suppl 1): 112–121.
|
| ［31］ |
Yoshida H, Shimizu T, Yoshioka M, et al. Management of portal hypertension based on portal hemodynamics[J]. Hepatol Res, 2021, 51(3): 251–262.
|
| ［32］ |
Guixé-Muntet S, Quesada-Vázquez S, Gracia-Sancho J. Pathophysiology and therapeutic options for cirrhotic portal hypertension[J]. Lancet Gastroenterol Hepatol, 2024, 9(7): 646–663.
|
| ［33］ |
McKenzie CV, Colonne CK, Yeo JH, et al. Splenomegaly: pathophysiological bases and therapeutic options[J]. Int J Biochem Cell Biol, 2018, 94: 40–43.
|
| ［34］ |
Dargan C, Habeebu SS, Mitchell GS, et al. Gamna-Gandy bodies present as a spleen mass in a patient with hereditary spherocytosis[J]. J Pediatr X, 2019, 1: 100010.
|
| ［35］ |
Saruwatari J, Dong C, Utsumi T, et al. Integrated analysis of microRNA and mRNA expression profiles in splenomegaly induced by non-cirrhotic portal hypertension in rats[J]. Sci Rep, 2018, 8(1): 17983.
|
| ［36］ |
Ye YT, Tang SH, Tai Y, et al. The transcriptomic profile shows the protective effects of celecoxib on cirrhotic splenomegaly[J]. Immunopharmacol Immunotoxicol, 2024, 46(1): 117–127.
|
| ［37］ |
Zhu XJ, Han W, Wang L, et al. Penicillar arterioles of red pulp in residual spleen after subtotal splenectomy due to splenomegaly in cirrhotic patients: A comparative study[J]. Int J Clin Exp Pathol, 2015, 8(1): 711–718.
|
| ［38］ |
Crane GM, Liu YC, Chadburn A. Spleen: development, anatomy and reactive lymphoid proliferations[J]. Semin Diagn Pathol, 2021, 38(2): 112–124.
|
| ［39］ |
Chu HB, Liu XF, Zhao JH, et al. Subtotal splenectomy for splenomegaly in cirrhotic patients[J]. Int J Clin Exp Pathol, 2014, 7(8): 4981–4990.
|
| ［40］ |
Weinzirl J, Scheffers T, Garnitschnig L, et al. Does the spleen have a function in digestion? Medical history, phylogenetic and embryological development of the splenogastric system[J]. Complement Med Res, 2020, 27(5): 357–363.
|
| ［41］ |
Specchi S, Bertolini G. CT angiography identifies collaterals in dogs with splenic vein obstruction and presumed regional splenic vein hypertension[J]. Vet Radiol Ultrasound, 2020, 61(6): 636–640.
|
| ［42］ |
Catucci D, Obmann VC, Berzigotti A, et al. Noninvasive assessment of clinically significant portal hypertension using deltaT1 of the liver and spleen and ECV of the spleen on routine Gd-EOB-DTPA liver MRI[J]. Eur J Radiol, 2021, 144: 109958.
|
| ［43］ |
Panda A, McCarthy MR, Murray JA, et al. Incidentally detected celiac disease with splenomegaly on (18)F FDG PET/CT: A potential lymphoma mimic[J]. Asia Ocean J Nucl Med Biol, 2021, 9(1): 51–55.
|
| ［44］ |
Rabiee A, Deng Y, Ciarleglio M, et al. Noninvasive predictors of clinically significant portal hypertension in NASH cirrhosis: validation of ANTICIPATE models and development of a lab-based model[J]. Hepatol Commun, 2022, 6(12): 3324–3334.
|
| ［45］ |
Liu J, Ma J, Yang C, et al. Impact of TIPS on splenic volume and thrombocytopenia[J]. AJR Am J Roentgenol, 2021, 216(3): 698–703.
|
| ［46］ |
Aldulaimi S, Mendez AM. Splenomegaly: diagnosis and management in adults[J]. Am Fam Physician, 2021, 104(3): 271–276.
|
| ［47］ |
Liu P, Zhu SS, Cao XG, et al. Endoscopic ultrasound-guided partial splenic embolization for hypersplenism: A novel alternative[J]. Endoscopy, 2024, 56(S 01): E144-E145.
|
| ［48］ |
Cao R, Lu X, Wu Y, et al. Laparoscopic splenectomy and esophagogastric devascularization versus endoscopic varices ligation plus laparoscopic splenectomy in the treatment of portal hypertension[J]. J Laparoendosc Adv Surg Tech A, 2023, 33(11): 1052–1057.
|
| ［49］ |
Liu K, Li Z, Li F, et al. Laparoscopic splenectomy with pericardial devascularization for hypersplenism and esophageal variceal hemorrhage due to portal hypertension[J]. J Vis Exp, 2024: 213.
|
| ［50］ |
Lin YK, Cai XR, Hong HJ, et al. Risk factors of portal vein system thrombosis after splenectomy: A meta-analysis[J]. ANZ J Surg, 2023, 93(12): 2806–2819.
|
| ［51］ |
Zhang Y, Lu H, Ji H, et al. Risk factors for a high comprehensive complication index after splenectomy plus pericardial devascularization for portal hypertension[J]. Turk J Gastroenterol, 2023, 34(10): 1041–1051.
|
| ［52］ |
Li HL, Ning SL, Gao YJ, et al. In situ subtotal spleen resection combined with selective pericardial devascularization for the treatment of portal hypertension[J]. World J Gastrointest Surg, 2023, 15(4): 634–642.
|
| ［53］ |
Chu HB, Han W, Wang L, et al. Long-term efficacy of subtotal splenectomy due to portal hypertension in cirrhotic patients[J]. BMC Surg, 2015, 15: 89.
|
| ［54］ |
Kheradpir MH. Late results of a modified new surgical procedure for the treatment of portal hypertension[J]. Eur J Pediatr Surg, 2007, 17(1): 17–22.
|
| ［55］ |
Petroianu A, De Oliveira AE, Alberti LR. Hypersplenism in schistosomatic portal hypertension[J]. Arch Med Res, 2005, 36(5): 496–501.
|
| ［56］ |
Magaz M, Giudicelli-Lett H, Abraldes JG, et al. Porto-sinusoidal vascular liver disorder with portal hypertension: natural history and long-term outcome[J]. J Hepatol, 2025, 82(1): 72–83.
|